Clinical Trial Details

Overview

Research Study Summary

A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza

Purpose

This 2-arm study will investigate the safety and tolerability of twice daily con ventional and double dose Tamiflu (oseltamivir) for the treatment of influenza i n immunocompromised patients. Eligible immunocompromised patients with laborator y-confirmed influenza will be randomized to receive either conventional dose (30 mg-75mg twice daily po, depending on age and weight) or double dose (60mg-150mg twice daily po depending on age and weight) Tamiflu for 10 days. Nasal and throa t swabs will be taken, and safety evaluations made, at intervals during the stud y. The anticipated time on study medication is 10 days and the anticipated time on study is 40 days.

To Learn more

CW ID: 203046
Date Last Changed: December 10, 2014

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
1 and up
Overall Status
Recruiting
Lead Sponsor
Genentech
Facility Type
N/A

Contact

Sharon Porth
University of South Florida - Tampa General Hospital
1 Tampa General Circle
Tampa, FL 33606
Phone: (813)844-8249

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.